Search Within
Applied Filters:
Showing 1-9 of 9 results for "


" within Papers
Raffaella Rossin et al.
Molecular pharmaceutics, 11(9), 3090-3096 (2014-08-01)
Radioimmunotherapy (RIT) of solid tumors is hampered by low tumor-to-nontumor (T/NT) ratios of the radiolabeled monoclonal antibodies resulting in low tumor doses in patients. Pretargeting technologies can improve the effectiveness of RIT in cancer therapy by increasing this ratio. We
Edyta Cędrowska et al.
Molecules (Basel, Switzerland), 25(5) (2020-02-29)
It has been proven and confirmed in numerous repeated tests, that the use of a combination of several therapeutic methods gives much better treatment results than in the case of separate therapies. Particularly promising is the combination of ionizing radiation
Pedro Gomes Sanches et al.
Bone, 75, 62-71 (2015-02-15)
Bone is one of the most common metastatic target sites in breast cancer, with more than 200 thousand new cases of invasive cancer diagnosed in the US alone in 2011. We set out to establish a multimodality imaging platform for
Usha Pandey et al.
Cancer biotherapy & radiopharmaceuticals, 34(5), 306-315 (2019-06-13)
Background: Transarterial radioembolization (TARE) represents an effective targeted therapeutic option for hepatocellular carcinoma (HCC), a cancer with high mortality
Ana Santidrián et al.
Physical chemistry chemical physics : PCCP, 22(18), 10063-10075 (2020-04-28)
In the present work, the effect of doping on electronic properties in bulk purified and filled arc-discharge single-walled carbon nanotubes samples is studied for the first time by in situ Raman spectroelectrochemical method. A major challenge to turn the potential
Sanjay Kumar Saxena et al.
Cancer biotherapy & radiopharmaceuticals, 32(10), 364-370 (2017-12-22)
The primary objective of this investigation is the development of a strategy for the synthesis of polyhydroxamic acid (PHA)-grafted cellulose film, its characterization, and evaluation of its usefulness for the preparation of
Swayamjeet Satapathy et al.
Clinical nuclear medicine, 45(9), e393-e399 (2020-07-01)
Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options. Peptide receptor radionuclide therapy (PRRT), being specific in targeting the somatostatin receptors, is a promising and viable option in this setting. In this study, we intended to
Swayamjeet Satapathy et al.
Nuclear medicine communications, 41(7), 629-635 (2020-05-07)
Peptide receptor radionuclide therapy (PRRT) has been shown to be useful in inoperable/metastatic medullary thyroid carcinoma (MTC). However, the role of concomitant PRRT and low-dose capecitabine therapy has not yet been studied in these patients. This study was conducted to
Sander M J van Duijnhoven et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 56(9), 1422-1428 (2015-07-15)
Radioimmunotherapy and nuclear imaging (immuno-PET/SPECT) of cancer with radiometal-labeled antibody fragments or peptides is hampered by low tumor-to-kidney ratios because of high renal radiometal retention. Therefore, we developed and evaluated a pretargeting strategy using click chemistry in vivo to reduce
Page 1 of 1
Page 1 of 1